Epidemiological and preclinical studies confirmed that activation of Akt is implicated in the pathogenesis of breast cancer also by conferring resistance to systemic treatments (Yang et al., 2016) and a number of molecules have been generated to selectively or nonselectively inhibit the three isoforms (Dey et al., 2017; Mundi et al., 2016). This evidence concerns the gene AKT1 and breast cancer.